0001958244-24-005724.txt : 20241112 0001958244-24-005724.hdr.sgml : 20241112 20241112080706 ACCESSION NUMBER: 0001958244-24-005724 CONFORMED SUBMISSION TYPE: 144 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20241112 DATE AS OF CHANGE: 20241112 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 144 SEC ACT: 1933 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 241443567 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: Kulkarni Samarth CENTRAL INDEX KEY: 0001682019 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 144 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS AG STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 144 1 primary_doc.xml 144 0001682019 XXXXXXXX LIVE 0001674416 CRISPR THERAPEUTICS AG 001-37923 Baarerstrasse 14 Zug V8 6300 41-41-561-32-77 Dr. Samarth Kulkarni Officer Common Goldman Sachs & Co. LLC 200 West Street New York NY 10282 75000 4114500 85353479 11/11/2024 NASDAQ Common 03/01/2021 Acquired as compensation -- Restricted Stock Awards Issuer N 868 03/01/2021 Compensation Common 12/01/2020 Acquired as compensation -- Restricted Stock Awards Issuer N 888 12/01/2020 Compensation Common 09/01/2021 Acquired as compensation -- Restricted Stock Awards Issuer N 880 09/01/2021 Compensation Common 03/10/2021 Acquired as compensation -- Restricted Stock Awards Issuer N 6307 03/10/2021 Compensation Common 06/01/2021 Acquired as compensation -- Restricted Stock Awards Issuer N 888 06/01/2021 Compensation Common 09/01/2020 Acquired as compensation -- Restricted Stock Awards Issuer N 888 09/01/2020 Compensation Common 12/01/2021 Acquired as compensation -- Restricted Stock Awards Issuer N 888 12/01/2021 Compensation Common 12/01/2019 Acquired as compensation -- Restricted Stock Awards Issuer N 926 12/01/2019 Compensation Common 12/03/2021 Acquired as compensation -- Restricted Stock Awards Issuer N 42182 12/03/2021 Compensation Common 06/01/2020 Acquired as compensation -- Restricted Stock Awards Issuer N 887 06/01/2020 Compensation Common 03/10/2022 Acquired as compensation -- Restricted Stock Awards Issuer N 6347 03/10/2022 Compensation Common 03/11/2022 Acquired as compensation -- Restricted Stock Awards Issuer N 4847 03/11/2022 Compensation Common 02/18/2023 Acquired as compensation -- Restricted Stock Awards Issuer N 2605 02/18/2023 Compensation Common 12/03/2022 Acquired as compensation -- Restricted Stock Awards Issuer N 336 12/03/2022 Compensation Common 12/03/2022 Acquired as compensation -- Restricted Stock Awards Issuer N 5263 12/03/2022 Compensation Y The sales of shares set forth herein are made in connection with a selling plan dated 6/13/2024 that is intended to comply with Rule 10b5-1(c). Filing intended to be made on 11/11/2024. Unable to be submitted due to federal holiday. 11/12/2024 06/13/2024 Goldman Sachs & Co. LLC on behalf of Samarth Kulkarni